Literature DB >> 23766536

APOL1 variants associate with increased risk of CKD among African Americans.

Meredith C Foster1, Josef Coresh, Myriam Fornage, Brad C Astor, Morgan Grams, Nora Franceschini, Eric Boerwinkle, Rulan S Parekh, W H Linda Kao.   

Abstract

Although case-control studies suggest that African Americans with common coding variants in the APOL1 gene are 5-29 times more likely than those individuals without such variants to have focal segmental glomerulosclerosis, HIV-associated nephropathy, or ESRD, prospective studies have not yet evaluated the impact of these variants on CKD in a community-based sample of African Americans. Here, we studied whether the APOL1 G1 and G2 risk alleles associate with the development of CKD and progression to ESRD by analyzing data from 3067 African Americans in the Atherosclerosis Risk in Communities Study who did not have CKD at baseline. Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry. Among participants who developed CKD, those participants with two risk alleles were more likely to progress to ESRD than their counterparts with zero or one risk allele (HR=2.22, 95% CI=1.01 to 4.84). In conclusion, APOL1 risk variants are risk factors for the development of CKD and progression from CKD to ESRD among African Americans in the general population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23766536      PMCID: PMC3752955          DOI: 10.1681/ASN.2013010113

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors.

Authors:  Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

3.  Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L.

Authors:  P N Duchateau; C R Pullinger; R E Orellana; S T Kunitake; J Naya-Vigne; P M O'Connor; M J Malloy; J P Kane
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

4.  End-stage renal disease in African-American and white men. 16-year MRFIT findings.

Authors:  M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; J Stamler
Journal:  JAMA       Date:  1997 Apr 23-30       Impact factor: 56.272

5.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

6.  Microalbuminuria as an early marker for cardiovascular disease.

Authors:  Dick de Zeeuw; Hans-Henrik Parving; Robert H Henning
Journal:  J Am Soc Nephrol       Date:  2006-07-06       Impact factor: 10.121

7.  Methods for high-density admixture mapping of disease genes.

Authors:  Nick Patterson; Neil Hattangadi; Barton Lane; Kirk E Lohmueller; David A Hafler; Jorge R Oksenberg; Stephen L Hauser; Michael W Smith; Stephen J O'Brien; David Altshuler; Mark J Daly; David Reich
Journal:  Am J Hum Genet       Date:  2004-04-14       Impact factor: 11.025

8.  Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors.

Authors:  T V Perneger; P K Whelton; M J Klag
Journal:  Arch Intern Med       Date:  1995-06-12

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

View more
  130 in total

1.  Generalizability of genetic findings related to kidney function and albuminuria.

Authors:  Afshin Parsa; Barry I Freedman
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 8.237

2.  APOL1 and progression of nondiabetic nephropathy.

Authors:  Nicholette D Palmer; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 10.121

3.  Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization.

Authors:  Hanghang Wang; Patrick H Pun; Lydia Kwee; Damian Craig; Carol Haynes; Megan Chryst-Ladd; Laura P Svetkey; Uptal D Patel; Elizabeth R Hauser; Martin R Pollak; William E Kraus; Svati H Shah
Journal:  Cardiorenal Med       Date:  2016-12-29       Impact factor: 2.041

4.  Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.

Authors:  Csaba P Kovesdy; Keith C Norris; L Ebony Boulware; Jun L Lu; Jennie Z Ma; Elani Streja; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Circulation       Date:  2015-09-18       Impact factor: 29.690

5.  Risk of ESRD in the United States.

Authors:  Patrick Albertus; Hal Morgenstern; Bruce Robinson; Rajiv Saran
Journal:  Am J Kidney Dis       Date:  2016-08-28       Impact factor: 8.860

6.  An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.

Authors:  DengFeng Li; James A Snipes; Mariana Murea; Anthony J A Molina; Jasmin Divers; Barry I Freedman; Lijun Ma; Snezana Petrovic
Journal:  Am J Nephrol       Date:  2020-08-31       Impact factor: 3.754

Review 7.  Genomic approaches in the search for molecular biomarkers in chronic kidney disease.

Authors:  M Cañadas-Garre; K Anderson; J McGoldrick; A P Maxwell; A J McKnight
Journal:  J Transl Med       Date:  2018-10-25       Impact factor: 5.531

8.  Familial clustering of ESRD in the Norwegian population.

Authors:  Rannveig Skrunes; Einar Svarstad; Anna Varberg Reisæter; Bjørn Egil Vikse
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 8.237

Review 9.  New insights on the risk for cardiovascular disease in African Americans: the role of added sugars.

Authors:  Karim R Saab; Jessica Kendrick; Joseph M Yracheta; Miguel A Lanaspa; Maisha Pollard; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2014-08-04       Impact factor: 10.121

10.  Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis.

Authors:  Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed
Journal:  Am J Nephrol       Date:  2015-08-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.